Circulating extracellular vesicles in the context of interstitial lung disease related to systemic sclerosis: A scoping literature review

被引:8
作者
De Lorenzis, Enrico [1 ,2 ,5 ]
Rindone, Andrea [1 ,3 ]
Di Donato, Stefano
Del Galdo, Francesco [1 ,4 ,5 ]
机构
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England
[2] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Div Rheumatol, Rome, Italy
[3] Univ Milan, ASST Gaetano Pini CTO Inst, Dept Rheumatol & Med Sci, Milan, Italy
[4] Leeds Teaching Hosp NHS Trust, NIHR Leeds Biomed Res Ctr, Leeds, England
[5] Chapel Allerton Hosp, Chapeltown Rd, Leeds LS7 4SA, W Yorkshire, England
关键词
Systemic sclerosis; Interstitial lung disease; Extracellular vesicles; Scoping review; MICROPARTICLES; EXOSOMES;
D O I
10.1016/j.autrev.2023.103401
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Interstitial lung disease (ILD) is a significant cause of disability and mortality in systemic sclerosis (SSc), where lung fibrosis stems from the interaction of cells within the epithelial, endothelial, interstitial, and immune cell compartments. Extracellular vesicles (EVs) are particles released by cells capable of transferring functionally active molecules, playing a crucial role in intercellular communication. This scoping review aims to identify and map existing evidence about the role of EVs as biomarkers or pathophysiological actors in SSc-ILD. It also retrospectively assesses the compliance of published articles with the current reporting guidelines established by the International Society of Extracellular Vesicles (ISEV). Methods: This scoping review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist. The searches were conducted up until 31 May 2023, with no restrictions on the starting year. Results: Out of 778 publications identified and screened, 9 references were selected. The eligible studies collectively involved a total of 539 SSc patients, with 220 patients presenting with ILD, as demonstrated by highresolution computed tomography. The studies largely focused on the quantitative assessment of EVs through flow cytometry, primarily concerning larger EVs. The studies primarily focused on the association of EV features with vascular complications, with fibrotic pulmonary involvement typically explored as a secondary finding. The evaluated patients' clinical characteristics were significantly heterogeneous across the studies as well as the association of EV features with the evidence of ILD but none of them longitudinally investigated the relationships with SSc-ILD prognosis. Adherence of these exploratory studies to ISEV reporting guidelines in terms of EV nomenclature, reporting of pre-analytic variables, and qualitative verification of EV separation products was incomplete. Conclusions: The evidence concerning the clinical association of EV features is limited and conflicting. The interpretation of available data is substantially biased due to patient selection tailored for vascular complications, heterogeneity of separation methodology, and a lack of validation procedures.
引用
收藏
页数:8
相关论文
共 27 条
[1]   Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation [J].
Banks, William A. ;
Sharma, Priyanka ;
Bullock, Kristin M. ;
Hansen, Kim M. ;
Ludwig, Nils ;
Whiteside, Theresa L. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) :1-21
[2]  
Bryon J, 2022, ARTHRITIS RHEUMATOL, V74, P2305
[3]   Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question! [J].
Colic, Jelena ;
Cerinic, Marco Matucci ;
Guiducci, Serena ;
Damjanov, Nemanja .
JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2020, 5 (01) :6-20
[4]   Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles [J].
Colombo, Marina ;
Raposo, Graca ;
Thery, Clotilde .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 30, 2014, 30 :255-289
[5]   Extracellular Vesicles in Pulmonary Fibrosis Models and Biological Fluids of Interstitial Lung Disease Patients: A Scoping Review [J].
d'Alessandro, Miriana ;
Bergantini, Laura ;
Bargagli, Elena ;
Vidal, Silvia .
LIFE-BASEL, 2021, 11 (12)
[6]   CONCORDANCE AND PROGNOSTIC RELEVANCE OF DIFFERENT DEFINITIONS OF SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE PROGRESSION [J].
De Lorenzis, E. ;
Natalello, G. ;
Di Donato, S. ;
Verardi, L. ;
Cerasuolo, P. G. ;
Kakkar, V. ;
D'agostino, M. A. ;
Del Galdo, F. ;
Bosello, S. L. .
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 :1633-1634
[7]   Microparticles: potential new contributors to the pathogenesis of systemic sclerosis? [J].
de Oliveira, Sandra Maximiano ;
Teixeira, Ighor Luiz de Azevedo ;
Franca, Carolina Nunes ;
Izar, Maria Cristina de Oliveira ;
Kayser, Cristiane .
ADVANCES IN RHEUMATOLOGY, 2023, 63 (01)
[8]   The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis [J].
Guiducci, Serena ;
Distler, Joerg H. W. ;
Juengel, Astrid ;
Huscher, Doerte ;
Huber, Lars C. ;
Michel, Beat A. ;
Gay, Renate E. ;
Pisetsky, David S. ;
Gay, Steffen ;
Matucci-Cerinic, Marco ;
Distler, Oliver .
ARTHRITIS AND RHEUMATISM, 2008, 58 (09) :2845-2853
[9]   Cross-sectional study of soluble selectins, fractions of circulating microparticles and their relationship to lung and skin involvement in systemic sclerosis [J].
Iversen, Line V. ;
Ullman, Susanne ;
Ostergaard, Ole ;
Nielsen, Christoffer T. ;
Halberg, Poul ;
Karlsmark, Tonny ;
Heegaard, Niels H. H. ;
Jacobsen, Soren .
BMC MUSCULOSKELETAL DISORDERS, 2015, 16
[10]  
Jud P, 2021, CLIN EXP RHEUMATOL, V39, pS57, DOI [10.55563/clinexprheumatol/243mpp, 10.55563/clinexprheumatol/243mpp]